BCR and glioblastoma: In the combined cohort of 93 patients (8 BCC, 12 Glioblastoma, 12 HNSCC, 61 Melanoma) across these four cancer types, overall survival was significantly better in patients exhibiting induced BCR clonal diversity following checkpoint blockade (Fig. 4B) (HR = 0.46 95% CI 0.245882 to 0.8678724, log-rank P = 0.0093).